2023-09-04 07:00:00
There are changes at the head of Sanofi. The French laboratory has indeed announced several appointments within its executive committee: a new R&D manager, a business operations manager and a new chief digital officer. Houman Ashrafian is appointed Executive Vice President and Head of R&D. He will take office on September 11, 2023. Since February, the French laboratory had been looking for a replacement for John Reed, who had left his post to join J&J.
Houman Ashrafian previously served as associate director of the investment platform SV Health Investors. H. Ashrafian also co-founded and managed several biotechs such as Alchemab Therapeutics and Mestag Therapeutics, and was vice-president and head of the clinical sciences group of the Belgian laboratory UCB. From 1is October 2023.
VOS INDICES
source
Madeleine Roach will become Business Operations Manager. In this capacity, she will be responsible for the growth of Sanofi’s activities and investments in scientific research. Mr. Roach joined Sanofi in 2022 as Head of Internal Audit and Risk Management following having held senior positions at AstraZeneca.
Sanofi is also changing chief digital officer, with the recruitment of Emmanuel Frenehard. He held management positions in several large companies for twenty years and joined Sanofi three years ago as Head of World, Digital.
Departure of Bill Sibold, Director of Specialty Medicine at Sanofi
Finally, Brian Foard will lead the Specialty Care entity on an interim basis, with immediate effect, following the departure of Bill Sibold, who is leaving Sanofi to pursue an external opportunity. An internal and external recruitment procedure has been launched to identify a successor to Bill Sibold.
“These appointments, which are the result of a harmonious balance between internal promotions and external recruitment, allow Sanofi to integrate three highly qualified personalities, with a fresh perspective and first-rate expertise in their respective fields. . (…) In the scientific field, our strategic ambition is to develop medicines and vaccines that will be the first or the best in their class in order to fuel the growth of our company in the years to come”commented Paul Hudson, the general manager of Sanofi.
Selected for you
1693921675
#Sanofi #executive #committee
